Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells
2001
Inhibition of CDK1 by indirubin derivatives in cancer cells
publication
Evidence: moderate
Author Information
Author(s): Marko D, Schätzle S, Friedel A, Genzlinger A, Zankl H, Meijer L, Eisenbrand G
Primary Institution: University of Kaiserslautern
Hypothesis
Indirubin and its derivatives inhibit CDK1 activity in human tumor cells, leading to growth inhibition.
Conclusion
Indirubin derivatives inhibit CDK1 activity, which is a key mechanism for their anti-tumor effects.
Supporting Evidence
- Indirubin-3′-monoxime causes MCF-7 cells to remain arrested in the G1/G0 phase of the cell cycle.
- Higher concentrations of indirubin-3′-monoxime lead to an increase in the G2/M phase cell population.
- A sub-G2 peak appears after 24 hours of treatment, indicating the onset of apoptosis.
- Indirubin-3′-monoxime induces dose-dependent inhibition of CDK1 activity.
Takeaway
This study shows that a compound called indirubin can stop cancer cells from growing by blocking a protein that helps them divide.
Methodology
The study investigated the effects of indirubin-3′-monoxime on CDK1 activity in MCF-7 human tumor cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website